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Interactions between ATP and ATP-binding proteins (ATPome) are
common and are required for most cellular processes. Thus, it is
clearly important to identify and quantify these interactions for
understanding basic cellular mechanisms and the pathogenesis of
various diseases. We used an ATP competition assay (competition
between ATP and acyl-ATP probes) that enabled us to distinguish
speciﬁc ATP-binding proteins from non-speciﬁc proteins (Adachi
et al., 2014) [1]. As a result, we identiﬁed 539 proteins, including
178 novel ATP-binding protein candidates. We also established an
ATPome selectivity proﬁling method for kinase inhibitors using our
cataloged ATPome list. Normally only kinome selectivity is proﬁled
in selectivity proﬁling of kinase inhibitors. In this data, we expand
the proﬁled targets from the kinome to the ATPome through per-
formance of ATPome selectivity proﬁling and obtained target
proﬁles of staurosporine and (S)-crizotinib. The data accompany-
ing the manuscript on this approach (Adachi et al., 2014) [1] have
been deposited to the ProteomeXchange with identiﬁer
PXD001200.
& 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
Adachi), tomonaga@nibiohn.go.jp (T. Tomonaga).
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 Large-scale and speciﬁc ATP binding protein catalog was obtained by ATP competition assay
(competition between ATP and acyl-ATP probes).
 539 proteins, including 178 novel ATP-binding protein candidates were identiﬁed. We also found
multiple ATP-competitive sites for several kinases, including epidermal growth factor receptor.
 As described in detail in the accompanying manuscript (DOI: 10.1021/pr500845u), we proved the
concept to expanding the proﬁled targets from the kinome to the ATPome through performance of
ATPome selectivity proﬁling.1. Data
In the present work, we provide the ATP binding protein catalog generated by ATP competition
assay including kinases and other ATP binding proteins [1]. We include a table containing quantitative
and qualitative information about ATP binding proteins and a supplemental ﬁgure in which all the
identiﬁed kinases are mapped.2. Materials and methods
2.1. Cell cultures
Hela-S3 cells were grown in DMEM with 10% fetal bovine serum plus antibiotics in 10% CO2 at 37 °C.
For SILAC labeling, Hela-S3 cells were cultured in DMEM supplemented with 10% dialyzed fetal bovine
serum and either 28.0 mg/L normal isotopic abundance arginine and 48.7 mg/L normal isotopic
abundance lysine (Light) or 28.0 mg/L arginine with six 13C and four 15N atoms and 48.7 mg/L lysine
with six 13C and two 15N atoms (Heavy) [2]. Labeling efﬁciency was conﬁrmed after ﬁve passages.
2.2. Sample preparation
Approximately 5108 Hela-S3 cells after each of the light and heavy SILAC labeling conditions were
harvested with 5 ml of ice-cold lysis buffer (25 mM Tris pH 7.5, 150 mM NaCl, 1% CHAPS, 1% Nonidet
P-40, protease inhibitor cocktail and phosphatase inhibitor cocktail). Cell lysate was incubated on ice for
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molecules in supernatants were removed by gel ﬁltration using a Zeba spin column (Pierce). Halt
protease/phosphatase inhibitor cocktail was then added to the sample. Cell lysate was diluted with
reaction buffer (20 mM Hepes pH 7.5, 150 mMNaCl, 0.1% Triton X100) to a ﬁnal protein concentration of
4 mg/mL. MnCl2 was added to 250 μL of lysates at a ﬁnal concentration of 20 mM. The labeling reaction
in the ATP-competition assay was carried out at a ﬁnal concentration of 5 μM ATP probe at room
temperature with gentle shaking for 10 min, following preincubation with ATP for 10 min. After the
reaction, the sample was denatured by 5 M urea, reduced with DTT (5 mM ﬁnal concentration), and
alkylated with iodoacetamide (20 mM ﬁnal concentration). The labeling reaction in the kinase inhibitor
experiment was performed similarly, with minor modiﬁcations. Kinase inhibitors were preincubated
for 10 min with SILAC-labeled “Light” lysate (1 mg protein), while SILAC-labeled “Heavy” lysate (1 mg
protein) were not treated with kinase inhibitors. After denaturation with urea, “Heavy” lysate was
spiked into an equal amount of “Light” lysate. After the alkylation step, the solution was substituted by
digestion buffer by gel ﬁltration followed by digestion at 37 °C overnight with sequencing-grade trypsin
at an enzyme/substrate ratio of 1:100. Labeled peptides were enriched by immobilized streptavidin
agarose resin. Prior to enrichment, 50 μL of slurry was washed 3 times with 500 μL of elution buffer
(50% acetonitrile, 0.1% TFA) and 3 times with 500 μL of digestion buffer. After addition to the digested
peptide solution, the mixture was incubated at room temperature for 1 h with gentle rotation. To
remove the unbound peptides, agarose resin was extensively washed with 2 ml of washing buffer
(25 mM Tris–HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40 and 5% glycerol), 2 ml of PBS, and
2 ml of pure H2O. After washing, labeled peptides were eluted with 150 μL of elution buffer (50% ACN,
0.1% TFA) twice and dried in a Speed-vac. Peptides were dissolved in 50 μL of 2 M urea and 1% TFA and
desalted using Stage Tips [3]. Each experiment was performed in triplicate or quadruplicate.
2.3. LC–MS/MS analysis
All nanoﬂow LC–MS/MS experiments were performed on a Q Exactive mass spectrometer (Thermo
Scientiﬁc). Data were acquired in data-dependent mode using Xcalibur software. The precursor ion scan
MS spectra (m/z 350–1800) were acquired in the Orbitrap with 70,000 resolution after accumulation of
ions to a 3106 target value. The twelve most intensive ions were isolated and fragmented in the
octopole collision cell by higher-energy collisional dissociation (HCD) with a maximum injection time of
120 ms and 35,000 resolution. In data-dependent LC/MS2 experiments dynamic exclusion was used with
20-s exclusion duration. Typical mass spectrometric conditions were as follows: spray voltage, 2 kV; no
sheath and auxiliary gas ﬂow; heated capillary temperature, 250 °C; normalized HCD collision energy
25%. The MS/MS ion selection threshold was set to 5104 counts. A 3.0 Da isolation width was chosen.
2.4. Data analysis
All raw ﬁles were processed by MaxQuant software suite (version 1.3.0.5) supported by the
Andromeda search engine for peptide identiﬁcation [4]. MaxQuant was used to score peptides for
identiﬁcation based on a search with an initial allowed mass deviation of the precursor ion of up to
7 ppm. The allowed fragment mass deviation was 20 ppm. Peak lists were searched against a con-
catenated forward and reversed version of the the UniProt human database (release 2011_11) combined
with 262 common contaminants was performed using the Andromeda search engine. Enzyme speci-
ﬁcity was set as C-terminal to Arg and Lys with allowed cleavage at proline bonds and a maximum of
three missed cleavages. Carbamidomethylation of cysteine was set as a ﬁxed modiﬁcation and
methionine oxidation and desthiobiotinylated lysine (þ196.1212 Da) as variable modiﬁcations. Peptides
and proteins were accepted with a false discovery rate of o1%. Feature matching between raw ﬁles was
enabled for ATP competition datasets using a retention time window of 2 min. We removed peptides
that were inhibited by o80% at 10 μM ATP in order to extract ATP-competitive peptides/sites from
label-free quantitation data. Peptides with quantitation values that were not reproducible were also
rejected, based on an average of o0.5 for three correlation coefﬁcients of intensity values in triplicate
experiments (correlation coefﬁcients of experiments 1 and 2, 2 and 3, 3 and 1); 89.6% of peptides were
rejected by this ﬁlter. MS spectra for all ATP-competitive peptides were checked for missed assignments
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recognized as ATP-competitive peptides. In the kinase inhibitor experiment, spike-in SILAC quantitation
was used instead of label-free quantitation. Peptides inhibited by 450% at 10 μM staurosporine were
accepted. MS spectra for all target peptides were checked manually.Acknowledgments
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